StockNews.AI
RVPH
StockNews.AI
5 hrs

Reviva to Participate in Key Opinion Leader Webinar Hosted by Alliance Global Partners

1. Reviva's CEO will discuss schizophrenia drug brilaroxazine in upcoming webinar. 2. The webinar features key opinion leaders discussing treatment landscapes. 3. Reviva's pipeline includes innovative drug candidates for unmet medical needs. 4. Brilaroxazine's phase 3 data will be highlighted during the discussion. 5. Reviva holds patents for its key drug candidates in multiple regions.

4m saved
Insight
Article

FAQ

Why Bullish?

Positive discussions on brilaroxazine's data can generate investor confidence; similar firms have seen stock gains from robust clinical data presentations.

How important is it?

The event could provide critical updates and insights, increasing market interest in RVPH's pipeline.

Why Short Term?

The immediate impact is due to the webinar's proximity to RVPH stock fluctuations generally influenced by news events; past examples include upward movement after significant announcements.

Related Companies

BRMDSAGEPTCT
October 07, 2025 16:08 ET  | Source: Reviva Pharmaceuticals CUPERTINO, Calif., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, PhD, Founder, President, and CEO of Reviva will participate in a fireside chat and key opinion leader (KOL) webinar hosted by A.G.P./Alliance Global Partners on October 10, 2025 at 11:00 AM ET. The webinar will feature an in-depth Fireside Chat with RVPH CEO Laxminarayan Bhat, PhD, and KOLs including Dr. Larry Ereshefsky, PharmD, BCPP, FCCP (Chief Scientific Officer, Follow the Molecule: CNS Consulting and Clinical Sciences by CenExel Research) and Dr. Mark Opler, PhD, MPH (Chief Research Officer at WCG Inc., Executive Director of the PANSS Institute, New York). The unmet medical need and current treatment landscape for patients suffering from symptoms of schizophrenia and the phase 3 clinical data of Reviva’s lead drug candidate brilaroxazine for schizophrenia will be discussed. The conversation will be moderated by A.G.P./Alliance Global Partners' James Molloy.  To register for the event, please click here. A replay of the webinar will be accessible in the investors section of Reviva’s website following the event. About Reviva Reviva is a late-stage biopharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva’s current pipeline focuses on the central nervous system (CNS), inflammatory and cardiometabolic diseases. Reviva’s pipeline currently includes two drug candidates, brilaroxazine (RP5063) and RP1208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both brilaroxazine and RP1208 in the United States, Europe, and several other countries. Corporate Contact:Reviva Pharmaceuticals Holdings, Inc.Laxminarayan Bhat, PhD www.revivapharma.com Investor Relations Contact:LifeSci Advisors, LLCPJ Kelleherpkelleher@lifesciadvisors.com

Related News